Post-Marketing Safety Surveillance of Adalimumab, Secukinumab, and Infliximab in Hidradenitis Suppurativa: An Analysis of the FDA Adverse Events Reporting System (FAERS) Database.

HOME
>
論文・技術情報
>
Post-Marketing Safety Surveillance of Adalimumab, Secukinumab, and Infliximab in Hidradenitis Suppurativa: An Analysis of the FDA Adverse Events Reporting System (FAERS) Database.

アブストラクト
ジャーナル名	Journal of the American Academy of Dermatology
Pubmed追加日	2025/2/21
投稿者	Joshi, Aditya; Gawey, Lauren; Saadi, Carissa; Naidoo, Pragna; Rick, Jonathan W; Park, Song Y; Cogen, Anna L; Daveluy, Steven D; Hsiao, Jennifer L; Shi, Vivian Y
組織名	Department of Dermatology, University of Washington, Seattle, WA; Creighton;University School of Medicine, Phoenix, AZ.;Department of Dermatology, University of Washington, Seattle, WA.;University of Arkansas School of Medicine, Little Rock, AR.;Department of Dermatology, University of California Davis, Sacramento, CA.;Department of Dermatology, Wayne State University, Detroit, MI.;Department of Dermatology, University of Southern California, Los Angeles, CA.;Department of Dermatology, University of Washington, Seattle, WA. Electronic;address: vivian.shi.publications@gmail.com.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/39978679/